PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9833600-0	1998	Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients.	Lisinopril	23-33	insulin	Homo sapiens	50-57	
9833600-1	1998	AIMS: The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives.	Lisinopril	76-86	insulin	Homo sapiens	142-149	
9833600-7	1998	GIR, used as an indicator of insulin sensitivity, was significantly increased by lisinopril (+1.5 mg min(-1) kg(-1), P<0.05 vs baseline) but not by losartan (+0.42 mg min(-1) kig(-1), NS), the difference between the two drugs being statistically significant (P<0.05).	Lisinopril	81-91	insulin	Homo sapiens	29-36	
9833600-9	1998	CONCLUSIONS: In conclusion, with all cautions due to an absence in this study of a randomized placebo phase, our findings suggest that lisinopril improved insulin sensitivity whereas losartan did not affect it.	Lisinopril	135-145	insulin	Homo sapiens	155-162	
9663927-13	1998	After treatment with lisinopril hypertensive patients with higher than normal insulin resistance indexes at baseline exhibited normalization of this parameter and significant increases of binding protein 1 levels and binding protein 1 : binding protein 3 ratio, with no significant changes in insulin-like growth factor I levels.	Lisinopril	21-31	insulin	Homo sapiens	78-85	
8837313-0	1996	The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters.	Lisinopril	18-28	insulin	Homo sapiens	44-51	
8837313-7	1996	Stimulated levels of insulin during glucose tolerance test also significantly decreased by lisinopril (peak insulin from 57 +/- 10 to 41.2 +/- 7.3 uU/ml, p < or = 0.02).	Lisinopril	91-101	insulin	Homo sapiens	21-28	
8837313-7	1996	Stimulated levels of insulin during glucose tolerance test also significantly decreased by lisinopril (peak insulin from 57 +/- 10 to 41.2 +/- 7.3 uU/ml, p < or = 0.02).	Lisinopril	91-101	insulin	Homo sapiens	108-115	
8837313-9	1996	Our data confirm a beneficial effect of lisinopril on plasma levels of insulin but failed to demonstrate any profibrinolytic effect in this study population, thus questioning the postulated mechanism of influencing endogenous fibrinolysis by changes of plasma insulin.	Lisinopril	40-50	insulin	Homo sapiens	71-78	
8751016-1	1995	To investigate the effects of antihypertensive treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril on insulin sensitivity and related metabolic variables, the insulin sensitivity index (SI), determined with the Minimal Model Method of Bergman, fasting plasma insulin and glucose concentrations, serum total triglyceride and lipoprotein cholesterol fractions, and blood pressure were assessed in 24 lean, non-diabetic patients with essential hypertension.	Lisinopril	112-122	insulin	Homo sapiens	126-133	
8751016-9	1995	These findings demonstrate that the ACE inhibitor lisinopril is neutral with regard to insulin sensitivity, plasma insulin and glucose, and lipoprotein metabolism in patients with essential hypertension.	Lisinopril	50-60	insulin	Homo sapiens	87-94	
8751016-9	1995	These findings demonstrate that the ACE inhibitor lisinopril is neutral with regard to insulin sensitivity, plasma insulin and glucose, and lipoprotein metabolism in patients with essential hypertension.	Lisinopril	50-60	insulin	Homo sapiens	115-122	
8281530-6	1993	The changes in daylong plasma glucose and insulin-stimulated glucose uptake increased after hydrochlorothiazide treatment and decreased following lisinopril.	Lisinopril	146-156	insulin	Homo sapiens	42-49	
25902654-1	2014	AIM: To assess effect of combined antihypertensive therapy with lisinopril and amlodipine on circadian blood pressure (BP), insulin resistance (IR), carbohydrate and lipid metabolism in patients with arterial hypertension (AH) and type 2 diabetes mellitus (DM).	Lisinopril	64-74	insulin	Homo sapiens	124-131	
9179532-2	1997	Lisinopril, like other ACE inhibitors, lowers blood pressure and preserves renal function in hypertensive patients with non-insulin-dependent or insulin-dependent diabetes mellitus (NIDDM or IDDM) and early or overt nephropathy, without adversely affecting glycaemic control or lipid profiles.	Lisinopril	0-10	insulin	Homo sapiens	124-131	
31926091-9	2020	Drug interactions may occur in patients who use premixed insulin with glimepiride, lisinopril, fenofibrate, candesartan, irbesartan, and gemfibrozil.	Lisinopril	83-93	insulin	Homo sapiens	57-64